Lincoln Pharmaceuticals Ratios

Lincoln Pharmaceuticals Ltd Ratios

The Lincoln Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Lincoln Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Lincoln Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Lincoln Pharmaceuticals Ltd (NSE: LINCOLN, BSE: 531633) is currently trading at ₹654.30, with a market capitalization of ₹12.97B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Lincoln Pharmaceuticals Ltd remains a key stock for fundamental analysis using Lincoln Pharmaceuticals Ltd Ratios.

Lincoln Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Lincoln Pharmaceuticals Ltd P/E ratio currently stands at 13.42, making it one of the most tracked metrics in Lincoln Pharmaceuticals Ltd Ratios.

Historically, the Lincoln Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 13.42
• 2023: 12.57
• 2022: 9.31
• 2021: 8.98
• 2020: 7.23

The rising Lincoln Pharmaceuticals Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Lincoln Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.64.

Historical P/B trend:

• 2024: 1.64
• 2023: 1.98
• 2022: 1.35
• 2021: 1.44

Lincoln Pharmaceuticals Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Lincoln Pharmaceuticals Ltd P/S ratio currently stands at 1.79, an important part of Lincoln Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 1.79
• 2023: 2.05
• 2022: 1.34
• 2021: 1.33

A stable or declining Lincoln Pharmaceuticals Ltd P/S ratio indicates cautious market sentiment.

Lincoln Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Lincoln Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 11.63.

Historical Lincoln Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 11.63
• 2023: 16.53
• 2022: 17.47
• 2021: 8.02
• 2020: 6.42

The declining Lincoln Pharmaceuticals Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Lincoln Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Lincoln Pharmaceuticals Ltd EV currently stands at ₹9.09B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 9.09B
• 2023: 10.21B
• 2022: 5.55B
• 2021: 5.09B

Lincoln Pharmaceuticals Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Lincoln Pharmaceuticals Ltd EV/EBITDA ratio is currently 9.39, a key metric in Lincoln Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 9.39
• 2023: 10.88
• 2022: 6.37
• 2021: 5.41

Stable Lincoln Pharmaceuticals Ltd EV/EBITDA indicates balanced valuation.

Lincoln Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Lincoln Pharmaceuticals Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Lincoln Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Lincoln Pharmaceuticals Ltd ROE currently stands at 13.02%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 13.02
• 2023: 17.04
• 2022: 15.59
• 2021: 17.16

Lincoln Pharmaceuticals Ltd maintains stable profitability levels.

Lincoln Pharmaceuticals Ltd Ratios Analysis Summary

The Lincoln Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Lincoln Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Lincoln Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.